MedTrace Logo

Image-derived Prediction of Response to Chemo-radiation in Glioblastoma

NCT02329795 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2017-10-12

No results posted yet for this study

Summary

This study seeks to investigate if advanced image-analysis of diagnostic scans, can be used to predict how aggressive brain tumors (glioblastoma) respond to standard chemo- and radiation treatment.

Conditions

Interventions

RADIATION

Radiotherapy

60 Gy in 30 fractions, 5 days a week, modulated arc therapy.

DRUG

Temozolomide

Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02329795 on ClinicalTrials.gov